Dublin, Sept. 12, 2017 -- The "The Global Market for Pain Management Drugs and Devices" report has been added to Research and Markets' offering.
The Global Market for Pain Management will Grow from Nearly $36.1 Billion in 2017 to $52.0 Billion by 2022, with a CAGR of 7.6% for the Period of 2017-2022
This report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management. The geographical scope of this study is global. This study will address acute versus chronic pain, treatments and regulatory issues facing healthcare workers. Also provided is detailed information based on product categories, use of products, forecasts and competitive analyses.
Report Includes
- An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers
- Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Examination of product categories, use of products, and the competitive landscape
- Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations
- Discussion of new regulatory requirements
- Comprehensive company profiles of major players in the industry
The report identifies two general segments of pain management:
- Pharmaceuticals.
- Devices.
Within the pharmaceuticals segment several sub-segments are discussed in detail including:
- Narcotic pain management.
- Non-narcotic pain management.
- Antimigraine treatments.
- Anesthetics.
- Other drugs (including CNS therapies).
The device segment covers several product lines and specifically targets the largest product segments including:
- Electrotherapy stimulators.
- Spine stimulators.
- Other products (including electromagnetic therapies and other treatments).
Each market segment provides detailed information based on product categories, product use, forecasts and competitive analyses.
A comparison of a treatment for the disease that naturally relieves the symptoms as compared to treatments for the relief of pain associated with the disease include:
Enbrel : Indicated for the treatment of moderate-to-severe rheumatoid arthritis.
Celebrex : Indicated for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and the management of acute pain.
The report is also evaluated in terms of application, discussing market trends and performance for the following areas:
- Surgical pain.
- Orthopedic/musculoskeletal pain.
- Migraine pain.
- Fibromyalgia pain.
- Cancer pain.
- Neuropathic pain.
- HIV/AIDS pain.
- Dental pain.
- General pain.
Key Topics Covered:
1: Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Methodology and Information Sources
- Geographic Breakdown
2: Summary and Highlights
- Overview
- Summary of the Major Markets
- Market Trends
- Undertreatment Issues
- Professional Pain Treatment Issues
- Access to Care
- FDA Requirements for Approval of Pain Therapies
- Drug Delivery Systems
3: Market and Technology Background
- History of Pain and Pain Treatment
- The Perception of Pain
- Types of Pain
- Assessment of Pain
- How Pain is Diagnosed
- How Pain is Treated
- Demographics and Aging Populations
- Pain Management Procedures: Steroids, Endoscopy, Fluoroscopy
- Alternative Methods of Pain Management
- Growing Trend in Cannabis Treatment for Pain
- Physical Pain Treatment Modalities
- Psychological Pain Therapies
- Tracking the Development of Complementary and Alternative Pain Control Methods
- Pain Management Services and Organizations
4: Industry Trends
- Overview
5: Treating Pain: Markets by Product Type
- Overview
- Pharmaceutical Pain Management
- Pain Management Devices
6: Market Breakdown by Application
- Pain Management by Application
7: Market Breakdown by Region
- Global Health Indicators
- Markets by Global Region
8: Industry Developments
- Timeline of Significant Industry Events and Developments
- Pharmaceutical Pipeline
- Pain Device Clinical Trials
- Patent Analysis
- The Brand/Generic Market Split
- Future of Pain Research
- Selected Pain-related Acquisitions and Alliances
9: Analysis of Market Opportunities
- Total Pain Management Market
- Table 65 : Market Opportunities for Pain Management Treatments, Through 2022
10: Company Profiles
- Abbott Laboratories
- Abbvie
- Allergan Plc
- Astrazeneca Plc
- Boston Scientific Corp.
- Depomed Inc.
- DJO Global Inc.
- ELI Lilly & Co.
- Endo International
- Glaxosmithkline
- Grunenthal Gmbh
- Hisamitsu Pharmaceutical Co. Inc.
- Johnson & Johnson
- Medtronic
- Novartis International AG
- Pfizer Inc.
- Purdue Pharma LP
11: Appendix A: Terminology and Sources of Information
- Pain Management Pharmaceutical Manufacturers and Developers
- U.S. Pain Societies and Associations
- International Associations and Organizations
- Table 85 : Glossary of terms used in Pain Management Drug and Device Markets
For more information about this report visit https://www.researchandmarkets.com/research/qfwnz5/the_global_market
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Medical Devices, Analgesics


Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Italy Fines Apple €98.6 Million Over App Store Dominance
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



